In a two-day meeting organised by ECDC and UNAIDS, representatives of 22 European countries discussed how to improve the delivery of HIV pre-exposure prophylaxis (PrEP) across Europe. The meeting brought together country delegates, PrEP users and community HIV advocates to seek ways to strengthen the provision and monitoring of PrEP.
Since its introduction in the 1990s, the main aim of combination antiretroviral therapy (ART) for HIV has been to halt the progression of the infection, maintaining the health of the HIV-positive person taking treatment. In addition to this, the impact of treatment as prevention has been well described.
This document provides EU/EEA Member States with evidence-based scientific advice on available options, when planning and implementing prevention and control interventions for blood-borne viruses in prison settings.
People in prison experience a higher burden of communicable diseases such as hepatitis B (HBV), hepatitis C (HCV) and HIV often linked to a history of injecting drug use.
This guidance is intended for policymakers responsible for the planning and delivery of healthcare services in the national or sub-national custodial system and all professionals responsible for the health and well-being of people in prison, including community-based service providers and those facilitating continuity of care in the community.
The objective of this report was to systematically review data on prevention and control of BBVs in prison settings, with a focus on the countries of the European Union (EU) and the European Economic Area (EEA).